Contraception
Volume 81, Issue 1 , Pages 79-85, January 2010

A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom® formulations in Cameroonian women

  • Francois-Xavier Mbopi-Keou

      Affiliations

    • Laboratoire de Santé Hygiène Mobile, Ministry of Public Health and Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon
  • ,
  • Sylvie Trottier

      Affiliations

    • Infectious Diseases Research Centre and Faculty of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Centre Hospitalier de l'Université Laval, Québec, Québec, Canada G1V 4G2
  • ,
  • Rabeea F. Omar

      Affiliations

    • Infectious Diseases Research Centre and Faculty of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Centre Hospitalier de l'Université Laval, Québec, Québec, Canada G1V 4G2
  • ,
  • Ngoh N. Nkele

      Affiliations

    • Yaounde Gynaecologic-Obstetric and Pediatric Hospital, Yaoundé, Cameroon
  • ,
  • Séraphin Fokoua

      Affiliations

    • Yaounde Gynaecologic-Obstetric and Pediatric Hospital, Yaoundé, Cameroon
  • ,
  • Enow R. Mbu

      Affiliations

    • Gynaecology Department and Faculty of Medicine and Biomedical Sciences, Central Hospital, University of Yaoundé I, Yaoundé, Cameroon
  • ,
  • Marc-Christian Domingo

      Affiliations

    • Infectious Diseases Research Centre and Faculty of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Centre Hospitalier de l'Université Laval, Québec, Québec, Canada G1V 4G2
  • ,
  • Jean-Francois Giguère

      Affiliations

    • Infectious Diseases Research Centre and Faculty of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Centre Hospitalier de l'Université Laval, Québec, Québec, Canada G1V 4G2
  • ,
  • Jocelyne Piret

      Affiliations

    • Infectious Diseases Research Centre and Faculty of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Centre Hospitalier de l'Université Laval, Québec, Québec, Canada G1V 4G2
  • ,
  • Anthony Mwatha

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, WA 98117, USA
  • ,
  • Benoît Mâsse

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, WA 98117, USA
  • ,
  • Michel G. Bergeron

      Affiliations

    • Infectious Diseases Research Centre and Faculty of Medicine, Université Laval, Centre Hospitalier Universitaire de Québec, Centre Hospitalier de l'Université Laval, Québec, Québec, Canada G1V 4G2
    • Corresponding Author InformationCorresponding author. Tel.: +1 418 654 2705; fax: +1 418 654 2715.

Received 20 April 2009; received in revised form 30 June 2009; accepted 7 July 2009. published online 25 August 2009.

Abstract 

Background

Invisible Condom® gel formulations being developed as microbicides to prevent the sexual transmission of HIV are advancing through the phases of clinical trials. The objectives of this study were to evaluate, after 8 weeks of vaginal application, the extended safety and acceptability of two Invisible Condom® vaginal gel formulations: (i) the polymer alone and (ii) the polymer containing sodium lauryl sulfate (SLS) compared to placebo.

Study Design

This study is a randomized, doubled-blind, placebo-controlled Phase II extended safety study in healthy sexually active women from Yaoundé, Cameroon. Women were randomized into three gel arms: (i) placebo, (ii) polymer alone and (iii) polymer/SLS. Women applied gel intravaginally twice daily for 8 weeks.

Results

A total of 194 sexually active women applied placebo (n=41), polymer alone (n=76) and polymer/SLS (n=77). Invisible Condom® gel formulations were well tolerated with no reported serious adverse events. The majority of reported adverse events were mild or moderate and mostly similar in all three arms, except for pelvic pain that was 10% higher in the polymer and polymer/SLS arms compared to placebo. Colposcopy showed neither genital ulceration nor mucosal lesions. Nugent score, H2O2-producing lactobacilli and vaginal pH were not affected by the study products. The gel formulations and applicator were generally acceptable and comfortable.

Conclusion

This extended safety study showed that the Invisible Condom® gel formulations and applicator were well tolerated and acceptable when applied intravaginally twice daily for 8 weeks. Thus, further phases of clinical development of Invisible Condom® as a potential microbicide to prevent sexual transmission of HIV are warranted.

Keywords: Randomized, Double-blind, Placebo-controlled trial, Invisible Condom®, Women, Cameroon, Vaginal microbicides, HIV/STI prevention

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0010-7824(09)00347-3

doi:10.1016/j.contraception.2009.07.002

Contraception
Volume 81, Issue 1 , Pages 79-85, January 2010